1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Wiltrom Co. Ltd.

Wiltrom Co. Ltd.

TTPEX:6767
24.10
TWD
+0.10
(+0.42%)
965.88MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.86
2.85
3.16
3.88
4.99
7.11
9.71
8.54
7.96
- -
Basic EPS, GAAP
-0.29
-1.18
0.3
-0.51
-1.64
-0.58
0.05
-1.25
-0.49
- -
Free Cash Flow per Basic Share
-0.99
-0.78
-2.04
-2.11
-1.55
-2.07
-1.84
-1.08
-0.37
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7.46
6.75
13.63
13.12
13.26
12.69
12.74
15.11
14.62
14.6
Tangible Book Value per Share
6.78
6.16
13.07
11.71
12.08
11.6
11.73
14.43
14.04
14.07
Basic Weighted Avg Shares
20
21
24
26
29
29
29
39
39
39
Sales/Revenue/Turnover
58
60
75
102
144
207
283
335
312
- -
Operating Margin (%)
-33.94
-67.17
-53.5
-44.81
-24.15
-4.73
-6.51
-14.45
-9.11
- -
Depreciation Expense
9
10
14
17
18
17
19
22
21
- -
Net Income, GAAP
-6
-25
7
-13
-47
-17
1
-49
-19
- -
Effective Tax Rate (%)
- -
- -
6.16
- -
- -
- -
7.3
- -
- -
- -
Profit Margin (%)
-10.29
-41.5
9.47
-13.02
-32.8
-8.21
0.53
-14.65
-6.13
- -
Working Capital
115
88
207
188
254
212
223
446
443
433
LT Debt
- -
- -
32
18
60
76
69
66
79
77
Total Equity
197
178
360
346
386
369
371
592
573
572
Return on Invested Capital (%)
- -
- -
-13.19
- -
- -
- -
-3.67
- -
- -
- -
Return on Capital (%)
- -
- -
2.7
- -
- -
- -
0.63
- -
- -
- -
Return on Common Equity (%)
- -
-13.24
2.65
-3.78
-12.94
-4.5
0.4
-10.19
-3.28
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
3
LT Borrowings
65
65
65
LT Finance Leases
13
13
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
39
39
Market Capitalization
1,093
1,066
966

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
502
488
479
Cash, Cash Equivalents & STI
366
337
327
Accounts Receivable, Net
64
70
77
Inventories
65
65
62
Total Current Liabilities
59
52
46
Payables & Accruals
- -
- -
- -
ST Debt
2
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.78%
-3.25%
Free Cash Flow
- -
-16.55%
-65.15%
Net Income, GAAP
- -
-675.8%
-61.05%
Sales/Revenue/Turnover
- -
26.5%
-6.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
75
76
90
94
335
2025
82
83
- -
64
312
2026
82
84
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.51
-0.31
-0.33
-0.47
-1.25
2025
0.13
-0.2
- -
-0.5
-0.49
2026
0.09
-0.1
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Huang Qian Liang
Full Time Employees
51
Sector
Health technology
Industry
Medical specialties
Address
No.26, Shengyi Road Zhubei TP Taiwan 30261
IPO Date
Jan 22, 2021
Website
wiltrom.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Wiltrom Co., Ltd. specializes in the research, development, production, and distribution of advanced implantable medical devices for spinal procedures across Taiwan and global markets. The company offers a comprehensive portfolio, including advanced spinal fixation apparatus, interbody fusion cages, materials for bone grafting, vertebral body augmentation devices, and specialized bone cements. Established in 2009 as a spin-off from the Industrial Technology Research Institute, Wiltrom is headquartered in Zhubei, Taiwan. With a strong emphasis on patented innovations like its Tripod-Fix system, the firm has secured international regulatory approvals, enabling its reach to extend into over 25 countries. They are actively pursuing expansion within European and American markets, driven by their commitment to enhancing orthopedic and spine surgery outcomes.